Long-term results of combined chemotherapy with gemcitabine and cisplatin for metastatic urothelial carcinomas

International Journal of Clinical Oncology

Volumn 15, Issue 4, 2010, Pages 369-375

  Tanji, Nozomu ^a   Ozawa, Akira ^a   Miura, Noriyoshi ^a   Yanagihara, Yutaka ^a   Sasaki, Toyokazu ^a   Nishida, Takayasu ^a   Kikugawa, Tadahiko ^a   Ikeda, Tetsuhiro ^a   Ochi, Tatsumasa ^a   Shimamoto, Kenji ^a   Aoki, Katsunori ^a   Yokoyama, Masayoshi ^a  

^a EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Cisplatin; Gemcitabine; Metastatic urothelial carcinoma

Indexed keywords

CISPLATIN; GEMCITABINE;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DUODENUM OBSTRUCTION; ERYTHROCYTE TRANSFUSION; FEBRILE NEUTROPENIA; FEMALE; FLUSHING; FOLLOW UP; GASTROINTESTINAL OBSTRUCTION; HEMORRHOID HEMORRHAGE; HUMAN; LIVER METASTASIS; LOCAL METASTASIS; LUNG INFILTRATE; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; REGIONAL METASTASIS; RETROSPECTIVE STUDY; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; UREA NITROGEN BLOOD LEVEL; UROGENITAL TRACT CANCER;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; CISPLATIN; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; JAPAN; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; UROLOGIC NEOPLASMS; UROTHELIUM;

EID: 77955710824     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10147-010-0069-2     Document Type: Article

References (11)

1. Saxman SB, Proper KJ, Einhorn LH et al (1997) Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study. J Clin Oncol 15:2564-2569
2. Bajorin DF, Dodd PM, Mazumdar M et al (1999) Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 17:3173-3181
3. Roth BJ, Bajorin D (1995) Advanced bladder cancer: The need to identify new agents in the post-M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin). World J Urol 153:894-900
4. von der Maase H, Hansen SW, Roberts JT et al (2000) Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 17:3068-3077
5. Kaufman D, Raghavan D, Carducci M et al (2000) Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J Clin Oncol 18:1921-1927
6. Moore MJ, Winquist E, Murray N et al (1999) Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: A Phase II trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 17:2876-2880
7. Ozawa A, Tanji N, Ochi T et al (2007) Gemcitabine and cisplatin for advanced urothelial carcinomas: The Ehime University Hospital experience. Int J Clin Oncol 12:279-283
8. von der Maase H, Sengelov L, Roberts JT et al (2005) Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 23:4602-4608
9. Suyama T, Ueda T, Fukasawa S et al (2009) Combination of gemcitabine and paclitaxel as second-line chemotherapy for advanced urothelial carcinoma. Jpn J Clin Oncol 39:244-250
10. Shinohara N, Harabayashi T, Suzuki S et al (2006) Salvage chemotherapy with paclitaxel, ifosfamide, and nedaplatin in patients with urothelial cancer who had received prior cisplatinbased therapy. Cancer Chemother Pharmacol 58:402-407
11. Barlesi F, Villani P, Doddoli C et al (2004) Gemcitabine-induced severe pulmonary toxicity. Fundam Clin Pharmacol 18:85-91